These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 25132263

  • 21. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.
    Oncogene; 2013 Sep 05; 32(36):4284-93. PubMed ID: 23045278
    [Abstract] [Full Text] [Related]

  • 22. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, Hu W, Yan Y, Feng J, Liao S, Wu P, Wang D, Wang S, Zhou J, Ma D.
    Hum Gene Ther; 2012 Jan 05; 23(1):32-45. PubMed ID: 21875334
    [Abstract] [Full Text] [Related]

  • 23. CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer.
    Shiomi M, Matsuzaki S, Serada S, Matsuo K, Mizuta-Odani C, Jitsumori M, Nakae R, Matsuzaki S, Nakagawa S, Hiramatsu K, Miyoshi A, Kobayashi E, Kimura T, Ueda Y, Yoshino K, Naka T, Kimura T.
    Cancer Sci; 2021 Sep 05; 112(9):3655-3668. PubMed ID: 34117815
    [Abstract] [Full Text] [Related]

  • 24. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR, Schorl C, Yano N, Romano N, Kim KK, Singh RK, Moore RG.
    J Ovarian Res; 2016 May 17; 9(1):28. PubMed ID: 27184254
    [Abstract] [Full Text] [Related]

  • 25. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
    Ma Y, Cao H, Lou S, Shao X, Lv W, Qi X, Liu Y, Ying M, He Q, Yang X.
    J Mol Med (Berl); 2015 Apr 17; 93(4):427-38. PubMed ID: 25411027
    [Abstract] [Full Text] [Related]

  • 26. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
    Wilson AJ, Saskowski J, Barham W, Yull F, Khabele D.
    J Ovarian Res; 2015 Jul 28; 8():46. PubMed ID: 26215403
    [Abstract] [Full Text] [Related]

  • 27. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, Ullo M, Orsulic S, Cheon DJ.
    Oncogene; 2018 Aug 28; 37(35):4809-4820. PubMed ID: 29769618
    [Abstract] [Full Text] [Related]

  • 28. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
    Hui C, Lan Z, Yue-li L, Li-lin H, Li-lin H.
    Reprod Sci; 2015 Dec 28; 22(12):1618-26. PubMed ID: 26079730
    [Abstract] [Full Text] [Related]

  • 29. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S, Fu GB, Tao Z, OuYang J, Kong F, Jiang BH, Wan X, Chen K.
    Oncotarget; 2015 Sep 22; 6(28):26457-71. PubMed ID: 26238185
    [Abstract] [Full Text] [Related]

  • 30. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
    Yeung BH, Kwan BW, He QY, Lee AS, Liu J, Wong AS.
    Oncogene; 2008 Dec 04; 27(53):6782-9. PubMed ID: 18776923
    [Abstract] [Full Text] [Related]

  • 31. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI, Kim JH, Lee KT, Choi JH.
    Gynecol Oncol; 2011 Dec 04; 123(3):588-96. PubMed ID: 21945308
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer.
    Lu M, Chen X, Xiao J, Xiang J, Yang L, Chen D.
    Arch Med Res; 2018 Feb 04; 49(2):84-88. PubMed ID: 29716743
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM, O'Toole SA, Spillane CD, Martin CM, Gallagher MF, Stordal B, Blackshields G, Sheils O, O'Leary JJ.
    BMC Cancer; 2015 Jul 25; 15():547. PubMed ID: 26205780
    [Abstract] [Full Text] [Related]

  • 36. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.
    Cell Signal; 2014 May 25; 26(5):1021-9. PubMed ID: 24463007
    [Abstract] [Full Text] [Related]

  • 37. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
    Busschots S, O'Toole S, O'Leary JJ, Stordal B.
    Exp Cell Res; 2015 Aug 01; 336(1):1-14. PubMed ID: 25499884
    [Abstract] [Full Text] [Related]

  • 38. Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors.
    Zhang Z, Liao H, Chen X, Zheng Y, Liu Y, Tao X, Gu C, Dong L, Duan T, Yang Y, Liu X, Yu Y, Feng Y.
    Eur J Obstet Gynecol Reprod Biol; 2011 Mar 01; 155(1):69-74. PubMed ID: 21074309
    [Abstract] [Full Text] [Related]

  • 39. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
    Sheng WJ, Jiang H, Wu DL, Zheng JH.
    Braz J Med Biol Res; 2013 Aug 01; 46(8):650-8. PubMed ID: 23969971
    [Abstract] [Full Text] [Related]

  • 40. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
    Wang M, Ma X, Wang J, Wang L, Wang Y.
    Int J Oncol; 2014 Apr 01; 44(4):1401-9. PubMed ID: 24535252
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.